. Disrupting serotonin or glutamate signaling reduces dopamine release in the nAcc core evoked by DR electrical stimulation. Related to Figure 4. A. Diagram showing electrical stimulation of DR neurons and measurement of dopamine release in the nAcc core by FSCV. B. DR electrical stimulation evoked dopamine release in the nAcc core. Representative color plot (top) and dopamine concentration trace (bottom) show increase in the release of dopamine in the nAcc core evoked by DR electrical stimulation. Top: Color plot topographically illustrates the voltammetric data with time on the x-axis, applied scan potential (Eapp) on the y-axis, and backgroundsubtracted faradaic current shown on the z-axis in pseudocolor. Dopamine is identified by an oxidation peak (green) at +0.6 V and a smaller reduction peak (yellow, top) at -0.2 V. Bottom: Corresponding tracer shows the concentration of dopamine (nM) detected in response to electrical stimulation. Onset of the bipolar stimulation was at 5 s with 300 µA, 60 Hz and 120 pulses (red bar). Inset shows characteristic dopamine voltammogram. C. Systemic administration of D2 receptor antagonist eticlopride increases release of dopamine in the nAcc core evoked by DR electrical stimulation. Top: Eticlopride treatment (2 mg/kg, i.p.) increases release of dopamine induced by DR electrical stimulation due to D2 autoreceptor blockade. Bottom: Corresponding tracer indicates the concentration of dopamine (nM) in response to electrical stimulation after systemic administration of eticlopride. Inset shows characteristic dopamine voltammogram. D. The 5-HT reuptake inhibitor fluoxetine does not change dopamine time course evoked by DR electrical stimulation in comparison with eticlopride treatment. Lines indicate dopamine concentrations in the nAcc core after DR electrical stimulation prior to drug treatment (baseline, green line), and after i.p. injection of fluoxetine (10 mg/kg, blue line) or eticlopride (2 mg/kg, pink line). E. Systemic administration of the 5-HT3 receptor antagonist ondansetron significantly decreases dopamine levels evoked by DR stimulation. Bars indicate dopamine concentrations in the nAcc core after DR electrical stimulation prior to drug treatment (baseline, green bar), and after injection of ondansetron (2 mg/kg, i.p., blue bar) or eticlopride (2 mg/kg, i. '). E. Microinjector tips in the VTA of SERT-ChR2-eYFP mice are indicated by red squares (ACSF group), green triangles (CNQX group) or purple circles (ondansetron group) in the schematic brain drawings. fr, fasciculus retroflexus; IPF, interpeduncular fossa; ml, medial lemniscus; RLi, rostral liner raphe; RPC, red nucleus parvicellular part; SNC, substantia nigra compacta part; SNR, substantia nigra reticulata part. F. Representative microdialysis probe tracks in the nAcc of a SERT-ChR2-eYFP mouse (bregma 1.10 mm). G. Microdialysis probes placements in the nAcc are indicated by red (ACSF group), green (CNQX group) or purple (ondansetron) line segments in the schematic brain drawings. aca, anterior commissure anterior part; AcbC, accumbens nucleus core; Acbsh, accumbens nucleus shell; CPu, caudate putamen; LV, lateral ventricle. Diagrams were adapted from mouse atlas. A. ChR2-eYFP mice spent more time in the laser-paired chamber on test day. Tracking data showing representative traces from a ChR2-eYFP (top) or an eYFP (bottom) mouse on test day. B. Laser stimulation does not alter locomotor activity. Bars show the average speed (m/s) for each group of mice in pretest day, laser-paired training days and test day (F1,24 =1.34, P = 0.26, SERT-ChR2-eYFP mice versus SERT-eYFP mice). C. Maximal (grey) and minimal (black) cellular viral infection within the DR. Coronal sections coordinates are indicated with reference to the mouse atlas. Aq, aqueduct; DR, dorsal raphe; mlf, medial longitudinal fasciculus; RtTg, reticulotegmental nucleus of the pons; scp, superior cerebellar peduncle; ts, tectospinal tract. D. Optical fibers placements and tips of microinjectors in VTA. Lines indicate the location of optical fibers within the VTA of SERT-ChR2-eYFP (green) or SERTeYFP (red) mice. Microinjector tips in VTA of SERT-ChR2-eYFP mice are indicated by green triangles (ACSF group), blue circles (ondansetron group), orange rectangles (ketanserin group) and purple squares (CNQX group). E. Diagram showing experiment timeline, virus injection in DR of SERT::Cre mice, and VTA optical activation of DR SERT terminals. F. VTA optical activation of DR inputs does not alter locomotor activity of SERT-ChR2-eYFP mice. Mouse locomotor activity were measured daily in an open field chamber in the five trials with and without optical stimulation (two-way ANOVA, optical stimulation effect: F1,9 = 1.201, P = 0.302. n = 10). All values are represented as mean + s.e.m. fr, fasciculus retroflexus; IPF, interpeduncular fossa; ml, medial lemniscus; RLi, rostral liner raphe; RPC, red nucleus parvicellular part; SNC, substantia nigra compacta part; SNR, substantia nigra reticulata part. A. Representative optical fiber track in VTA of a SERT-ChR2-eYFP mouse. B. Optical fibers placements in the VTA are indicated by blue (VGluT3-ChR2-eYFP mice) or orange (SERT-ChR2-eYFP mice) line segments in the schematic brain drawings. fr, fasciculus retroflexus; IPF, interpeduncular fossa; ml, medial lemniscus; RLi, rostral liner raphe; RPC, red nucleus parvicellular part; SNC, substantia nigra compacta part; SNR, substantia nigra reticulata part. Table S1 . Frequency of TH neurons coexpressing 5-HT3A mRNA in the VTA a . Related to a TH neurons coexpressing 5-HT3A mRNA were counted in 12 µm thick sections from 3 different rats (subject 1, 2, 3). n = total number of TH neurons coexpressing 5-HT3A mRNA in the VTA. Figure 3I 0.00010 2.5 s vs. baseline Newman -keuls post hoc test Figure 3I 0.00221 3.5 s vs. baseline Newman -keuls post hoc test Figure 3I 0.00062 4.5 s vs. baseline Newman -keuls post hoc test Figure 3I 0.00004 5.5 s vs. baseline Newman -keuls post hoc test Figure 3I 0.01470 6.5 s vs. baseline Newman -keuls post hoc test Figure 3J 0.00005116 1.5 s vs. baseline Newman -keuls post hoc test Figure 3J 0.00001685 2.5 s vs. baseline Newman -keuls post hoc test Figure 3J 0.00001593 3.5 s vs. baseline Newman -keuls post hoc test Figure 3J 0.00005513 4.5 s vs. baseline Newman -keuls post hoc test Figure 3J 0.00004830 5.5 s vs. baseline Newman -keuls post hoc test Figure 3J 0 
